Arena Pharmaceuticals (ARNA) Message Board

To: tuck who wrote (1811)	3/29/2012 3:10:11 PM
From: scaram(o)uche	Read Replies (1) of 1849

>> but did not allay CV concerns << Yeah, just one of the bottom lines that FDA could adopt in briefing docs. Drug was designed to be a safe 2C agonist, a fen replacement. In FDA's analysis, there's still a signal. What's good for orex...... I still haven't heard an analyst ask about non-statsig results here, about titration signals..... Time to death specifically attributed to mammary adenocarcinoma was significantly decreased only in the lorcaserin high-dose group. In a second analysis which assumed deaths due to unspecified mammary tumor in rats with both fibroadenoma and adenocarcinoma were caused by adenocarcinoma, time to death was accelerated in the lorcaserin mid-dose group as well, although the incidence of mammary adenocarcinoma was not increased over controls in the mid-dose group.